Epigenetics of myelodysplastic syndromes
|
Nov 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
|
Feb 2018
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index
|
Sep 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
|
Nov 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients
|
Feb 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
|
Jan 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
|
Jun 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodyspla
|
Feb 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood - a prospective study by EWOG-MDS.
|
Jun 2013
|
Leukemia
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria
|
Jan 2021
|
Leukemia
|
paroxysmal nocturnal hemoglobinuria (PNH)
|